在接受免疫检查点抑制剂治疗的患者中使用-葡萄糖共载体-2 抑制剂
Moran Gvili Perelman1,2, Rafael Y Brzezinski1,2, Barliz Waissengrin3,2
1Division of Cardiology, Tel-Aviv Sourasky Medical Center, Tel Aviv, Israel.
Cardio-oncology (London, England)
|January 11, 2024
概括
-葡萄糖共传输体2抑制剂 (SGLT2i) 在接受免疫检查点抑制剂 (ICI) 的2型糖尿病癌症患者中显著降低了全因死亡率. 在这个人群中,SGLT2i也可能对心脏毒性有好处.
科学领域:
- 在瘤学瘤学.
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
背景情况:
- 免疫检查点抑制剂 (ICI) 已经改变了癌症治疗.
- 糖尿病 (DM) 对ICI患者的结果产生负面影响.
- -葡萄糖携带载体2抑制剂 (SGLT2i) 改善心血管状况,降低糖尿病患者的死亡率.
研究的目的:
- 评估SGLT2i对所有原因死亡率的预后影响.
- 评估SGLT2i对ICI治疗的癌症患者心脏毒性的影响.
主要方法:
- 用ICI治疗的2型DM (DM2) 癌症患者的回顾性分析.
- 用SGLT2i治疗和没有SGLT2i治疗的患者之间的结果比较.
- 主要终点:所有原因的死亡率. 二级终点:主要不良心血管事件 (MACE).
主要成果:
- 在28个月内,与非SGLT2i组 (95名患者) 相比,SGLT2i组 (24名患者) 的全因死亡率显著降低 (21%对59%,p=0.002).
- 没有观察到MACE的显著差异.
- 在SGLT2i组中发生了零例心肌炎和心房动,而在非SGLT2i组中分别发生了2例和6例.
结论:
- 在接受ICI治疗的DM2癌症患者中,SGLT2i治疗与全因死亡率的降低有关.
- 需要进一步的研究来阐明机制,并证实SGLT2i在此背景下对心脏有毒性的益处.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
188
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
188
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
176
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
176
Secondary Active Transport
120.1K
One example of how cells use the energy contained in electrochemical gradients is demonstrated by glucose transport into cells. The ion vital to this process is sodium (Na+), which is typically present in higher concentrations extracellularly than in the cytosol. Such a concentration difference is due, in part, to the action of an enzyme “pump” embedded in the cellular membrane that actively expels Na+ from a cell. Importantly, as this pump contributes to the high concentration of...
120.1K
Glucose Transporters
22.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.8K
Tumor Immunotherapy
527
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
Glucose Absorption Into the Small Intestine
31.7K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.7K


